{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-002839","form_type":"8-K","ticker":"CARM","cik":"0001485003","company_name":"Carisma Therapeutics Inc.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.753693+00:00","generated_at":"2026-05-28T03:08:03.868069+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Carisma updates pipeline: CT-1119 Phase 1 start H1 2025, liver fibrosis IND in 2026","bullets":["CT-1119 (mesothelin-targeted CAR-Monocyte) Phase 1 trial with tislelizumab in solid tumors expected to start H1 2025.","Phase 1 trial to enroll up to 12 patients in China; initial safety/efficacy data anticipated Q4 2025.","Liver fibrosis program: preclinical in 2025 to enable regulatory submission in 2026, followed by Phase 1 in 2026.","Corporate presentation updated on company website with these pipeline milestones."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-002839","json":"https://secwatch.observer/filing/0001104659-25-002839.json","markdown":"https://secwatch.observer/filing/0001104659-25-002839.md","text":"https://secwatch.observer/filing/0001104659-25-002839.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1485003/000110465925002839/0001104659-25-002839-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1485003/000110465925002839/tm253058d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T03:08:03.868069+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}